Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial

Overview of attention for article published in Frontiers in Pharmacology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,941 followers.

New HERBAL MEDICINE Research Available. Click Here to Access Article(s): https://t.co/mMapWDJ9Hv

07 Feb 2023

Reply Repost Favourite

11-8-22: China recently approved: Genuine Biotech's reverse transcriptase inhibitor, Azvudine, for treating hepatitis C & COVID-19 Shanghai Junshi Biosciences' VV116 (deuremidevir hydrobromide) and Simcere Pharma's Xiannuoxin (simnotrelvir-plus-ritona

06 Feb 2023

Reply Repost Favourite

New Research: Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial https://t.co/WWDXZ1n4II #pharmacology

19 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.